Five-year financial record for the year ended 31 March Consolidated income statement 1 2 2013 2012 2011 2010 2009 m m m m m Revenue 233.7 197.0 111.4 98.5 84.8 Cost of sales 67.2 56.3 34.1 32.8 37.1 Gross profit 166.5 140.7 77.3 65.7 47.7 Selling, general and administrative expenses 58.0 48.9 33.7 25.3 19.7 Contribution 108.5 91.8 43.6 40.4 28.0 Amortisation and impairment of acquired intangibles assets 43.4 30.7 10.0 9.1 3.0 Amortisation of repurchase of contractual rights 9.6 Foreign exchange gains losses 3.1 2.6 2.0 4.0 0.9 Research and development 41.2 39.7 32.1 26.7 21.2 Profit on disposal of assets and investments 0.4 0.2 1.5 1.1 2.6 Amounts written off property, plant and equipment 1.8 3.0 Amounts written off associates and investments 0.2 1.4 3.4 Acquisition and reorganisation costs 0.1 1.1 3.8 0.7 10.9 Share of results of associates 0.3 0.4 Operating profit loss 25.7 19.9 13.8 2.1 9.2 Net financial expense income 1.6 3.1 3.0 7.0 2.1 Profit loss before tax 24.1 23.0 10.8 9.1 11.3 Tax 7.7 8.4 20.0 2.2 1.8 Profit loss after tax for the year 16.4 14.6 9.2 11.3 13.1 Earnings loss per share Basic 5.0p 4.5p 3.4p 4.4p 7.1p Diluted 5.0p 4.4p 3.4p 4.4p 7.1p 1 The results for the year ended 31 March 2011 include the results of Biocompatibles International plc from the date of acquisition, being 27 January 2011.
2 The results for the year ended 31 March 2009 include the results of Protherics PLC from the date of acquisition, being 4 December 2008.
2 The statement of financial position for 31 March 2009 includes the assets and liabilities acquired from Protherics PLC during the year.
Consolidated cash flow statement 1 2 2013 2012 2011 2010 2009 m m m m m Net cash from used in operating activities 55.5 47.2 12.0 5.8 1.8 Net cash used in from investing activities 4.5 3.9 5.5 2.6 21.8 Net cash from used in financing activities 0.2 0.2 0.6 1.4 0.1 Increase decrease in cash and cash equivalents 51.2 43.1 18.1 4.6 19.9 Effect of exchange rate fluctuations on cash held 0.6 0.1 0.8 0.2 1.3 Cash and cash equivalents at start of year 106.9 63.7 82.6 78.2 57.0 Cash and cash equivalents at end of year 158.7 106.9 63.7 82.6 78.2 1 The results for the year ended 31 March 2011 include the results of Biocompatibles International plc from the date of acquisition, being 27 January 2011.
Financials 141 Five-year financial record BTG plc Annual Report and Accounts 2013 Shareholder information Financial calendar Circulation of Annual Report for the year ended 31 March 2013 14 June 2013 Annual General Meeting 16 July 2013 Announcement of interim results for the six months ended 30 September 2013 November 2013 Preliminary announcement of annual results for the year ended 31 March 2014 May 2014 Shareholders At 31 March 2013 there were 10,116 holders of ordinary shares in the Company.
Their shareholdings are analysed as follows: Percentage of total Number of Percentage Number of number of ordinary of ordinary Size of shareholding shareholders shareholders shares shares 1 to 5,000 9,310 92.0 6,399,541 1.9 5,001 to 50,000 563 5.6 8,235,782 2.5 50,001 to 100,000 66 0.6 4,783,654 1.5 100,001 to 500,000 109 1.1 25,558,769 7.8 Over 500,000 68 0.7 283,299,125 86.3 Total 10,116 100.0 328,276,871 100.0 Shareholders are further analysed as follows: Percentage of total Number of Percentage Number of number of ordinary of ordinary Type of owner shareholders shareholders shares shares Bank and nominee companies 956 9.5 311,588,514 94.9 Private shareholders 8,969 88.7 12,061,479 3.7 Limited companies 65 0.6 788,206 0.2 BTG Employee Share Trust 1 1,063,029 0.3 Insurance companies and pension funds 125 1.2 2,775,643 0.9 10,116 100.0 328,276,871 100.0 Mutual funds and other institutions, and private shareholders holding their shares within PEPs and ISAs, are included within Bank and nominee companies.
Capita share dealing services A quick and easy share dealing service is available from Capita Registrars, to either buy or sell more shares.
An online and telephone dealing facility is available providing shareholders with an easy-to-access and simple-to-use service.
For further information on this service, or to buy and sell shares, please contact: www.
com online dealing or 44 0 871 664 0454 telephone dealing calls cost 10p per minute plus network extras.
Lines are open from 8 am to 4.30 pm, Monday to Friday If calling from outside the UK: 44 0 203 367 2686.
Full terms, conditions and risks apply and are available on request or by visiting www.
This is not a recommendation to buy or sell shares.
The price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Shareholder change of address The Company offers the facility, in conjunction with Capita Registrars, our Registrars, to conduct a number of routine matters via the web including the ability to notify any change of address.
If you are a shareholder and are either unable or would prefer not to use this facility, please do not send the notification to the Companys registered office.
Please write direct to Capita Registrars, at their address shown below, where the register is held.
Financials 142 Shareholder information BTG plc Annual Report and Accounts 2013 Financials Registered office and head office Advisers BTG plc Stockbrokers 5 Fleet Place J. P. Morgan Cazenove London 25 Bank Street EC4M 7RD Canary Wharf Tel: 44 0 20 7575 0000 London E14 5JP Fax: 44 0 20 7575 0010 Tel: 44 0 20 7742 4000 Email: info@btgplc.
com Deutsche Bank AG London Registered number 2670500 Winchester House 1 Great Winchester Street London EC2N 2DB Tel: 44 0 20 3142 8700 Fax: 44 0 20 3142 8735 Auditors KPMG Audit Plc 15 Canada Square London E14 5GL Tel: 44 0 20 7311 1000 Fax: 44 0 20 7311 3311 Registrars Capita Registrars The Registry 34 Beckenham Road Beckenham Kent BR3 4TU Callers from the UK: Tel: 44 0 871 664 0300 Please note that calls cost 10p per minute, plus network extras.
Lines are open from 9am to 5.30pm, Monday to Friday.
Callers from outside the UK: Tel: 44 0 208 639 3399 Financials 143 Shareholder information BTG plc Annual Report and Accounts 2013
